[ET Net News Agency, 13 March 2025] BOCI lowered the target price for Genscript Bio
(01548) to HKD21 from HKD29 and maintained the "buy" rating.
The research house said looking ahead into 2025, CDMO and synthetic biology are expected
to play a greater role in revenue contribution despite the persisting execution risks.
(rc)